Epithelial-mesenchymal transition sensitizes breast cancer cells to cell death via the fungus-derived sesterterpenoid ophiobolin A
Open Access
- 20 May 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-10
Abstract
The epithelial–mesenchymal transition (EMT) imparts properties of cancer stem-like cells, including resistance to frequently used chemotherapies, necessitating the identification of molecules that induce cell death specifically in stem-like cells with EMT properties. Herein, we demonstrate that breast cancer cells enriched for EMT features are more sensitive to cytotoxicity induced by ophiobolin A (OpA), a sesterterpenoid natural product. Using a model of experimentally induced EMT in human mammary epithelial (HMLE) cells, we show that EMT is both necessary and sufficient for OpA sensitivity. Moreover prolonged, sub-cytotoxic exposure to OpA is sufficient to suppress EMT-imparted CSC features including sphere formation and resistance to doxorubicin. In vivo growth of CSC-rich mammary cell tumors, is suppressed by OpA treatment. These data identify a driver of EMT-driven cytotoxicity with significant potential for use either in combination with standard chemotherapy or for tumors enriched for EMT features.Keywords
All Related Versions
Funding Information
- Cancer Prevention and Research Institute of Texas (RP180771)
This publication has 73 references indexed in Scilit:
- The role of taxanes in triple-negative breast cancer: literature reviewDrug Design, Development and Therapy, 2015
- Landscape of Neoadjuvant Therapy for Breast CancerAnnals of Surgical Oncology, 2015
- Pathological Complete Response in Neoadjuvant Treatment of Breast CancerAnnals of Surgical Oncology, 2015
- Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancerJournal of Cancer Research and Clinical Oncology, 2011
- Triple-Negative Breast Cancer: An Unmet Medical NeedThe Oncologist, 2011
- Triple-Negative Breast CancerNew England Journal of Medicine, 2010
- Triple-negative breast cancerBreast Cancer Research, 2010
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast CancerJournal of Clinical Oncology, 2008
- Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant ChemotherapyJournal of Clinical Oncology, 2007
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 2007